Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00037492 · ClinicalTrials.gov registry record · Phase 3
Families In Recovery From Stroke Trial (F.I.R.S.T.)
A Phase 3 study, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
- Completed
- Registry status
- Phase 3
- Development phase
- 291
- Enrollment target
NCT00037492: Completed Phase 3 study, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
NCT00037492 is a Phase 3 study that has completed, run by National Institute of Neurological Disorders and Stroke (NINDS). The registered enrollment target is 291 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00037492, a Phase 3 study, has completed, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 291 participants
- Enrollment target
Study Summary
The purpose of this trial is to assess the effects of a psychosocial intervention on functional recovery after stroke.
Interventions
- PROCEDURE home-based sessions/family meetings with trained clinician
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 291 participants |
| Phase | Phase 3 |
What the finished NCT00037492 record still lists
NCT00037492 is an interventional study that assigns participants to a tested intervention. The registered 291 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 1 intervention - of which home-based sessions/family meetings with trained clinician is the first listed.
NCT00037492 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00037492 about?
NCT00037492 is a clinical study titled "Families In Recovery From Stroke Trial (F.I.R.S.T.)". The purpose of this trial is to assess the effects of a psychosocial intervention on functional recovery after stroke.
What is the current status of trial NCT00037492?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 291 participants.
What interventions are being tested in trial NCT00037492?
The interventions under investigation include: home-based sessions/family meetings with trained clinician (PROCEDURE).
Who is sponsoring clinical trial NCT00037492?
This trial is sponsored by National Institute of Neurological Disorders and Stroke (NINDS), which has 567 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00037492's enrollment target sits among peer trials
291 1168th of 2000 higher than 830 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02074839 · 291 participants · Phase 1
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
- NCT03769766 · 291 participants · Phase 3
Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance
- NCT06563479 · 291 participants · Phase 3
A Study Comparing Personalized Radiation Therapy With Standard Radiation Therapy in People With HPV-Positive Throat Cancer
- NCT04429542 · 292 participants · Phase 1
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors